¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ Rl cL(HM  
} G{"Mp4  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© ~;$QSO\2h  
?Ybq]J\q  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© zdPJ>PNU  
6c^?DLy9B  
1.Co-stimulators (or co-stimulating molecules) m,kYE9 {  
g,iW^M  
2.NK-kB ~v\ W[  
/"`hz6rIv  
3.Immunoglobulin superfamily O, eoO,gB  
%pxJ27Q  
4.antigen-presenting cell (APC) L / PAC  
|) ~-Wy  
5.death domain UZFs ]z!,k  
qY%|Uo  
6.CCR and CXCR TtrO_D  
M __S)  
7.Lectin (or mitogen) w3 vZ}1|  
7& P70DO  
8.Clusters of differentiation, CD) 5V(#nz  
F|+B8&-v  
9.B7 family -a|b .p  
(FGy"o%TP'  
10.Cytotoxic T lymphocyte, CTL) 'z}9BGR !  
_VgFuU$h  
11.IL-15 and IL-15 receptor (IL-15R) !!ZGNZ_  
QPp31o.!5  
12.MHC restriction hFycSu  
eV(.\Lj  
13.Affinity-chromatography JDa_;bqL  
E[ -yfP~[  
14.Cyctosprin A, CsA (  -q0!]E  
%}N01P|X>  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) _?felxG[  
,@ p4HN*  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© R86i2',  
9k62_]w@6  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 "UY34a ^I  
s+ *LVfau  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ U . <c#S  
&'/PEOu&}G  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ leSBR,C  
ODpAMt"  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© YGyw^$.w  
v ?nGAn  
ÃâÒßѧרҵ£º F!I9)PSj  
SFP?ND+7  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ $LU| wW  
]-heG'y]{  
Ïû»¯ÄÚ¿Æ£º y{P~!Yn|  
?u{Mz9:?HT  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 1v|0&{lB  
V^ ;l g[:  
ѪҺ²¡Ñ§×¨Òµ£º 7<8'7<X  
-@'R YY=  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»